HomeCompareEYEN vs O

EYEN vs O: Dividend Comparison 2026

EYEN yields 26.46% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EYEN wins by $73.4K in total portfolio value
10 years
EYEN
EYEN
● Live price
26.46%
Share price
$7.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.6K
Annual income
$12,760.49
Full EYEN calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — EYEN vs O

📍 EYEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEYENO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EYEN + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EYEN pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EYEN
Annual income on $10K today (after 15% tax)
$2,248.68/yr
After 10yr DRIP, annual income (after tax)
$10,846.42/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, EYEN beats the other by $6,509.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EYEN + O for your $10,000?

EYEN: 50%O: 50%
100% O50/50100% EYEN
Portfolio after 10yr
$70.9K
Annual income
$8,931.62/yr
Blended yield
12.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

EYEN
No analyst data
Altman Z
-9.4
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EYEN buys
0
O buys
0
No recent congressional trades found for EYEN or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEYENO
Forward yield26.46%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$107.6K$34.2K
Annual income after 10y$12,760.49$5,102.74
Total dividends collected$69.8K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: EYEN vs O ($10,000, DRIP)

YearEYEN PortfolioEYEN Income/yrO PortfolioO Income/yrGap
1← crossover$13,346$2,645.50$10,818$608.16+$2.5KEYEN
2$17,579$3,299.59$11,787$741.68+$5.8KEYEN
3$22,872$4,062.02$12,946$911.00+$9.9KEYEN
4$29,412$4,939.21$14,345$1,127.94+$15.1KEYEN
5$37,407$5,936.07$16,056$1,409.05+$21.4KEYEN
6$47,081$7,055.73$18,171$1,777.83+$28.9KEYEN
7$58,676$8,299.52$20,820$2,268.21+$37.9KEYEN
8$72,451$9,666.86$24,188$2,929.90+$48.3KEYEN
9$88,677$11,155.27$28,533$3,837.11+$60.1KEYEN
10$107,645$12,760.49$34,235$5,102.74+$73.4KEYEN

EYEN vs O: Complete Analysis 2026

EYENStock

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Full EYEN Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this EYEN vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EYEN vs SCHDEYEN vs JEPIEYEN vs KOEYEN vs MAINEYEN vs STAGEYEN vs ADCEYEN vs NNNEYEN vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.